AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
A phase 1/2 trial of Elranatamab, Pomalidomide, Dexamethasone in multiple myeloma, run by AstraZeneca, now recruiting.
Overview
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma is a phase 1/2 interventional study registered as NCT06106945 by AstraZeneca, with 226 participants planned, started 2023-12-05 and due to reach its primary completion in 2027-08-16. Interventions recorded: AZD0305, Elranatamab, Pomalidomide, Dexamethasone. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Shares Elranatamab, Pomalidomide, Dexamethasone, Multiple myeloma.
- TrialMagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other
Shares Elranatamab, Pomalidomide, Dexamethasone, Multiple myeloma.
- TrialA Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex)
Shares Pomalidomide, Dexamethasone, Multiple myeloma.
- TrialA Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatama
Shares Elranatamab, Dexamethasone, Multiple myeloma.
- TrialA Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma
Shares Pomalidomide, Dexamethasone, Multiple myeloma.
- TrialA Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatme
Shares Pomalidomide, Dexamethasone, Multiple myeloma.
- TrialA Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)
Shares Pomalidomide, Dexamethasone, Multiple myeloma.
- TrialA Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide
Shares Elranatamab, Dexamethasone, Multiple myeloma.